MET and thyroid cancer: High c-Met expression was observed in 12% of iCCA and 16% of eCCA and portends a poor prognosis, while MET amplifications are observed in 2–7% BTCs.63 Cabozantinib, a multi-kinase small molecule inhibitor that potently inhibits MET64 and is FDA-approved for advanced renal cell carcinoma and thyroid cancer, showed limited activity and significant toxicity in a study of unselected CCA, and response did not correlate with MET expression.65 However, MET amplification may be a more potent driver than MET expression.